Efficacy of switch therapy in community-acquired pneumonia in Japan

Japanese Journal of Chemotherapy

Volumn 57, Issue 5, 2009, Pages 423-429

  Yanagihara, Katsunori ^a   Morinaga, Yoshitomo ^a   Yamada, Koichi ^a   Nakamura, Shigeki ^a   Kurihara, Shintaro ^a   Yamamoto, Kazuko ^a   Imamura, Yoshifumi ^a   Izumikawa, Koichi ^a   Seki, Masafumi ^a   Kakeya, Hiroshi ^a   Yamamoto, Yoshihiro ^a   Kamihira, Shimeru ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Community acquired pneumonia; Cost effectiveness; CRP; Switch therapy

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEPHEM DERIVATIVE; LINCOMYCIN; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE;

AGED; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUGHING; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; FEMALE; HOSPITAL PATIENT; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 71049153305     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Ramirez J A, Srinath L, Ahkee S, Huang A, Raff M J: Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia Arch Intern Med 1995; 155: 1273-1276
2. Hendrickson J R, North D S: Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 1995; 29: 561-565
3. Castro-Guardiola A, Viejo-Rodríguez A L, Soler-Simon S, Armengou-Arxé A, Bisbe-Company V, Peñarroja-Matutano G, et al: Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 2001; 111: 367-374 (Pubitemid 32913669)
4. Vetter N, Cambronero-Hernandez E, Rohlf J, Simon S, Carides A, Oliveria T, et al; Protocol 020 Study Group: A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther 2002; 24: 1770-1785 (Pubitemid 35440949)
5. Lode H, File T M Jr, Mandell L, Ball P, Pypstra R, Thomas M; 185 Gemifloxacin Study Group: Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone / oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 2002; 24: 1915-1936 (Pubitemid 35440959)
6. Fine M J, Auble T E, Yealy D M, Hanusa B H, Weissfeld L A, Singer D E, et al: A prediction rule to identify low risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250
7. Guideline for the Management of Adults with Community-acquired Pneumonia Am J Respir Crit Care Med 2001; 163: 1730-1754
8. Saito A, Kohno S, Matsushima T, Watanabe A, Oizumi K, Yamaguchi K, et al; Study Group: Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. J Infect Chemother 2006; 12: 63-69
9. Jpn J Antibiot 2007; 60: 200-205